EP1015642A4 - Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida - Google Patents

Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida

Info

Publication number
EP1015642A4
EP1015642A4 EP99933581A EP99933581A EP1015642A4 EP 1015642 A4 EP1015642 A4 EP 1015642A4 EP 99933581 A EP99933581 A EP 99933581A EP 99933581 A EP99933581 A EP 99933581A EP 1015642 A4 EP1015642 A4 EP 1015642A4
Authority
EP
European Patent Office
Prior art keywords
hiv
aids
monitoring
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99933581A
Other languages
German (de)
English (en)
Other versions
EP1015642A1 (fr
Inventor
Christos J Petropoulos
Jeanette Whitcomb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of EP1015642A1 publication Critical patent/EP1015642A1/fr
Publication of EP1015642A4 publication Critical patent/EP1015642A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP99933581A 1998-06-24 1999-06-24 Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida Withdrawn EP1015642A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10429598A 1998-06-24 1998-06-24
PCT/US1999/014486 WO1999067427A1 (fr) 1998-06-24 1999-06-24 Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida
US104295 2002-03-22

Publications (2)

Publication Number Publication Date
EP1015642A1 EP1015642A1 (fr) 2000-07-05
EP1015642A4 true EP1015642A4 (fr) 2005-03-23

Family

ID=22299700

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99933581A Withdrawn EP1015642A4 (fr) 1998-06-24 1999-06-24 Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida

Country Status (9)

Country Link
EP (1) EP1015642A4 (fr)
JP (1) JP2003503004A (fr)
CN (1) CN1154747C (fr)
AU (1) AU769927B2 (fr)
BR (1) BR9912209A (fr)
CA (1) CA2341679A1 (fr)
MX (1) MXPA00012843A (fr)
NZ (1) NZ508981A (fr)
WO (1) WO1999067427A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
ATE404698T1 (de) 2000-04-18 2008-08-15 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
AU2007203337B2 (en) * 2000-04-18 2009-12-17 Virco Bvba Methods for measuring drug resistance
AU2002226316B2 (en) 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
ATE432506T1 (de) 2002-07-01 2009-06-15 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
TW200413720A (en) 2002-07-01 2004-08-01 Virologic Inc Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
JP2005536200A (ja) 2002-07-01 2005-12-02 バイロロジック，インコーポレーテッド プロテアーゼ阻害剤に対する病原性ウイルスの感受性を決定するための組成物および方法
CA2490764C (fr) 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une transcriptase inverse du vih-1 correles a une resistance phenotypique aux medicaments
US8178291B2 (en) 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
WO2006130477A2 (fr) 2005-05-27 2006-12-07 Monogram Biosciences, Inc. Procedes et compositions pour determiner la resistance du vih-1 a des inhibiteurs de protease
US8071284B2 (en) 2005-06-06 2011-12-06 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs
US10480037B2 (en) 2011-09-23 2019-11-19 Laboratory Corporation Of America Holdings Methods and systems for predicting HIV-1 coreceptor tropism
CN103965302B (zh) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 一种重组超抗原seb突变体，其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027319A1 (fr) * 1996-01-29 1997-07-31 Virologic, Inc. Compositions et procedes pour determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux et criblage de medicaments antiviraux
WO1997027332A1 (fr) * 1996-01-26 1997-07-31 Innogenetics N.V. Procede de detection de mutations induites par des medicaments dans le gene de la transcriptase reverse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027332A1 (fr) * 1996-01-26 1997-07-31 Innogenetics N.V. Procede de detection de mutations induites par des medicaments dans le gene de la transcriptase reverse
WO1997027319A1 (fr) * 1996-01-29 1997-07-31 Virologic, Inc. Compositions et procedes pour determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux et criblage de medicaments antiviraux

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLERCQ DE E: "DEVELOPMENT OF RESISTANCE OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) TO ANTI-HIV AGENTS: HOW TO PREVENT THE PROBLEM?", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, AMSTERDAM, NL, vol. 9, no. 1, 1997, pages 21 - 36, XP000878561, ISSN: 0924-8579 *
FITZGIBOON J E ET AL: "HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 POL GENE MUTATIONS IN AN AIDS PATIENT TREATED WITH MULTIPLE ANTIRETROVIRAL DRUGS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 67, no. 12, December 1995 (1995-12-01), pages 7271 - 7275, XP002934804, ISSN: 0022-538X *
IVERSEN A K N ET AL: "MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 STRAINS RESULTING FROM COMBINATION ANTIRETROVIRAL THERAPY", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 2, 1 February 1996 (1996-02-01), pages 1086 - 1090, XP002031823, ISSN: 0022-538X *
KANKI P J ET AL: "VIROLOGY OF HIV-1 AND HIV-2: IMPLICATIONS FOR AFRICA", AIDS, LONDON, GB, vol. 11, no. SUPPL B, 1997, pages S33 - S42, XP008035289, ISSN: 0269-9370 *
See also references of WO9967427A1 *

Also Published As

Publication number Publication date
AU769927B2 (en) 2004-02-12
CN1332804A (zh) 2002-01-23
BR9912209A (pt) 2002-11-05
WO1999067427A9 (fr) 2000-03-30
EP1015642A1 (fr) 2000-07-05
JP2003503004A (ja) 2003-01-28
NZ508981A (en) 2004-02-27
MXPA00012843A (es) 2002-04-24
WO1999067427A1 (fr) 1999-12-29
AU4961199A (en) 2000-01-10
CN1154747C (zh) 2004-06-23
CA2341679A1 (fr) 1999-12-29

Similar Documents

Publication Publication Date Title
EP1015642A4 (fr) Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida
HUP0104814A3 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
HK1037981A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C.
AU2002351397A8 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
HK1050126A1 (zh) 治療人食管異常組織的方法和系統
EP1200086A4 (fr) Procedes therapeutiques ou prophylactiques de la douleur et de l'anxiete
IL157577A0 (en) Disposable underpants and method of providing the same
EP1194587A4 (fr) Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida
EP1191941A4 (fr) Methode de prophylaxie et/ou de traitement de troubles cliniques
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
HUP0002030A3 (en) Use of glur5 receptorantagonists for the treatment of pain
AU8136801A (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
EP1034003A4 (fr) Procedes de traitement des infections par le vih ou autres infections utilisant un activateur de lymphocytes t ou un activateur viral et therapie d'association anti-retrovirale
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
EP1100386A4 (fr) Outil de coupe chirurgical et procede d'utilisation correspondant
GB9804886D0 (en) Therapeutic combination
IL127351A0 (en) Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV
HUP0100844A3 (en) Method of increasing the biovaliability and tissue penetration of azithromycin
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
EP1152781A4 (fr) Dialyse et traitement sanguins
PT1355668E (pt) Utilização de inibidores da il-18 para o tratamento e/ou prevenção de doença cardíaca
AU2001266863A1 (en) Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
IL121036A0 (en) Method of enhancing cognition
IL141211A0 (en) Prevention and treatment of viral disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20050202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONOGRAM BIOSCIENCES, INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1030631

Country of ref document: HK

17Q First examination report despatched

Effective date: 20050923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081210